RAFAEL HOLDINGS, INC. Debt Conversion, Converted Instrument, Amount
RAFAEL HOLDINGS, INC. (RFL) reported Debt Conversion, Converted Instrument, Amount of $37.84 million for the 12-month period ending 2025-07-31, per its 10-K filed 2025-10-29.
Financial Statements › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2025-10-29
- RAFAEL HOLDINGS, INC. debt conversion, converted instrument, amount for the quarter ending 2025-07-31 was $0.00.
- RAFAEL HOLDINGS, INC. debt conversion, converted instrument, amount for the quarter ending 2025-04-30 was $0.00, a 100.00% decline year-over-year.
- RAFAEL HOLDINGS, INC. debt conversion, converted instrument, amount for the quarter ending 2025-01-31 was $0.00.
- RAFAEL HOLDINGS, INC. debt conversion, converted instrument, amount for the quarter ending 2024-10-31 was $37.84M.
- RAFAEL HOLDINGS, INC. debt conversion, converted instrument, amount for fiscal 2025 was $37.84M, a 0.00% change from fiscal 2024.
- RAFAEL HOLDINGS, INC. debt conversion, converted instrument, amount for fiscal 2024 was $37.84M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2025-07-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29 | $0.00 derived: sum of 2 quarters · filed 2025-10-29 | $0.00 derived: sum of 3 quarters · filed 2025-10-29 | $37.84M 10-K · filed 2025-10-29 |
| 2025-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-11 | $0.00 derived: sum of 2 quarters · filed 2025-06-11 | $37.84M 10-Q · filed 2025-06-11 | $37.84M derived: sum of 4 quarters · filed 2025-06-11 |
| 2025-01-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-03-14 | $37.84M 10-Q · filed 2025-03-14 | $37.84M derived: sum of 3 quarters · filed 2025-03-14 | $46.49M derived: sum of 4 quarters · filed 2025-03-14 |
| 2024-10-31 | $37.84M 10-Q · filed 2024-12-11 | $37.84M derived: sum of 2 quarters · filed 2024-12-20 | $46.49M derived: sum of 3 quarters · filed 2024-12-20 | |
| 2024-07-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | $8.64M derived: sum of 2 quarters · filed 2024-12-20 | $37.84M 10-K/A · filed 2024-12-20 | |
| 2024-04-30 | $8.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-06-14 | $37.84M 10-Q · filed 2024-06-14 | ||
| 2024-01-31 | $29.20M 10-Q · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |